AU2007274295A1 - Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta T cell activators - Google Patents

Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta T cell activators Download PDF

Info

Publication number
AU2007274295A1
AU2007274295A1 AU2007274295A AU2007274295A AU2007274295A1 AU 2007274295 A1 AU2007274295 A1 AU 2007274295A1 AU 2007274295 A AU2007274295 A AU 2007274295A AU 2007274295 A AU2007274295 A AU 2007274295A AU 2007274295 A1 AU2007274295 A1 AU 2007274295A1
Authority
AU
Australia
Prior art keywords
group
cat
cell activator
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007274295A
Other languages
English (en)
Inventor
Christine Bezombes
Jean-Jacques Fournie
Julie Gertner
Guy Laurent
Helene Sicard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Innate Pharma SA
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Innate Pharma SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of AU2007274295A1 publication Critical patent/AU2007274295A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007274295A 2006-07-13 2007-07-12 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta T cell activators Abandoned AU2007274295A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06291146.6 2006-07-13
EP06291146A EP1878440A1 (en) 2006-07-13 2006-07-13 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds
US92420807P 2007-05-03 2007-05-03
US60/924,208 2007-05-03
PCT/EP2007/057217 WO2008006895A2 (en) 2006-07-13 2007-07-12 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators

Publications (1)

Publication Number Publication Date
AU2007274295A1 true AU2007274295A1 (en) 2008-01-17

Family

ID=37708304

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007274295A Abandoned AU2007274295A1 (en) 2006-07-13 2007-07-12 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta T cell activators

Country Status (6)

Country Link
US (1) US20090304688A1 (https=)
EP (2) EP1878440A1 (https=)
JP (1) JP2009544582A (https=)
AU (1) AU2007274295A1 (https=)
CA (1) CA2658222A1 (https=)
WO (1) WO2008006895A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2150258A2 (en) * 2007-06-01 2010-02-10 Innate Pharma S.A. Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
US8735624B2 (en) 2008-09-10 2014-05-27 Innate Pharma Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
KR101940430B1 (ko) 2014-08-07 2019-01-18 가꼬우호우징 효고 이카다이가쿠 Il-18과 분자 표적 항체를 병용하는 암 치료약
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
CN116064678A (zh) 2016-01-15 2023-05-05 美国基因技术国际有限公司 用于活化γ-δT细胞的方法和组合物
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
WO2017156311A2 (en) 2016-03-09 2017-09-14 American Gene Technologies International Inc. Combination vectors and methods for treating cancer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT
AU2017292582C1 (en) 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
EP3487507A4 (en) 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
JP2020524996A (ja) 2017-06-16 2020-08-27 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド ヒトガンマデルタｔ細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
CA3114292A1 (en) * 2018-09-27 2020-04-02 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
CN109529050A (zh) * 2018-12-07 2019-03-29 广州市妇女儿童医疗中心 Vγ9δ2T细胞、治疗肺癌的药物ZOL和hMSH2协同作用的应用
KR20230042035A (ko) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
US20240148827A1 (en) * 2021-03-11 2024-05-09 The Methodist Hospital Methods and Compositions for Treatment of Disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
FR2715660A1 (fr) 1994-01-28 1995-08-04 Centre Nat Rech Scient Composés organo-phosphorés activateurs des lymphocytes Tgammadelta, procédé pour préparer et/ou isoler et/ou caractériser ces composés, compositions et utilisations pharmaceutiques.
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
WO2005054258A2 (en) * 2003-12-02 2005-06-16 Innate Pharma New class of gamma delta t cells activators and use thereof
WO2005067635A2 (en) * 2004-01-06 2005-07-28 Hava Corp. Telephone with automatic switching between cellular and voip networks
ATE419008T1 (de) * 2004-04-26 2009-01-15 Innate Pharma Adjuvante zusammensetzung und anwendungsverfahren dafür
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT

Also Published As

Publication number Publication date
US20090304688A1 (en) 2009-12-10
WO2008006895A2 (en) 2008-01-17
CA2658222A1 (en) 2008-01-17
EP1878440A1 (en) 2008-01-16
EP2040750A2 (en) 2009-04-01
JP2009544582A (ja) 2009-12-17
WO2008006895A3 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
AU2007274295A1 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta T cell activators
US12384847B2 (en) Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
TWI838196B (zh) 抗cd38抗體之皮下調配物及其用途
JP6816038B2 (ja) 抗ｃｄ３８抗体及びサバイビン阻害剤による血液悪性疾患の併用療法
US12186304B2 (en) Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule
EP4653463A2 (en) Antibodies
RU2723937C2 (ru) Композиции, включающие антитела к cd38 и карфилзомиб
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
US12097199B2 (en) Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
US20220025061A1 (en) Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
US20230134748A1 (en) Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
JP2019524780A (ja) プロテアソーム阻害剤及び抗ｃｄ３０抗体の組み合わせ
WO2023073645A1 (en) Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
TWI724046B (zh) 以抗ｃｄ３８抗體與生存素抑制劑於血紅素惡性腫瘤之組合治療
HK40015605A (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
HK40015605B (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
BR112017002729B1 (pt) Terapia de combinação kit para tratar um tumor sólido em um indivíduo, anticorpo ou porção de ligação a antígeno do mesmo, uso e composição farmacêutica

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application